Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.thromres.2012.09.011PMID 23058466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

  2012cited by this paper
• Prevention and prediction of inhibitor risk

  2012cited by this paper
• Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

  2012cited by this paper
• Patient and parent preferences for haemophilia A treatments

  2011cited by this paper
• EUHASS: The European Haemophilia Safety Surveillance system.

  2011cited by this paper
• Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on‐demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

  2011cited by this paper
• Concentrate‐related inhibitor risk: is a difference always real?

  2011cited by this paper
• A commentary on the differences in pharmacokinetics between recombinant and plasma‐derived factor IX and their implications for dosing

  2011cited by this paper
• Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.

  2011cited by this paper
• Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies

  2011cited by this paper
• Characterization of γ-Carboxylated Tryptic Peptides by Collision-Induced Dissociation and Electron Transfer Dissociation Mass Spectrometry

  2011cited by this paper
• Glycosylation of Therapeutic Proteins

  2010cited by this paper
• Purification and characterization of a new recombinant factor VIII (N8)

  2010cited by this paper
• From human to humans: Introducing the first recombinant human FVIII product produced from a human cell line

  2010cited by this paper
• Cost of care of haemophilia with inhibitors

  2010cited by this paper
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

  2010influential reference
• Functional roles of the factor VIII B domain

  2009cited by this paper
• Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products

  2009cited by this paper
• Role of Glycosylation in Conformational Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII

  2009cited by this paper
• Back to the future: a recent history of haemophilia treatment

  2008cited by this paper
• The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008influential reference
• The tertiary structure and domain organization of coagulation factor VIII.

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008influential reference
• Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment

  2008cited by this paper
• The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance.

  2008influential reference
• The disappearing act of factor VIII

  2008cited by this paper
• The role of VWF for the success of immune tolerance induction.

  2008cited by this paper
• Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates

  2007cited by this paper
• A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

  2007cited by this paper
• Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A

  2007influential reference
• Affibody-mediated transferrin depletion for proteomics applications.

  2007cited by this paper
• Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

  2006cited by this paper
• Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors

  2006cited by this paper
• Challenges in therapeutic glycoprotein production.

  2006cited by this paper
• Post-translational modifications in the context of therapeutic proteins

  2006influential reference
• Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins

  2006influential reference
• Xenotransplantation and ABO incompatible transplantation: the similarities they share.

  2006cited by this paper
• Recombinant vs. plasma‐derived products, especially those with intact VWF, regarding inhibitor development

  2006cited by this paper
• GlyProt: in silico glycosylation of proteins

  2005cited by this paper
• The promise and challenges of bioengineered recombinant clotting factors

  2005cited by this paper
• Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates

  2004cited by this paper
• Recombinant expression systems in the pharmaceutical industry

  2004cited by this paper
• Appropriate glycosylation of recombinant proteins for human use

  2004influential reference
• Charge analysis of N-Glycans from human recombinant coagulation factor VIII and human FVIII standards

  2004cited by this paper
• High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6

  2003cited by this paper
• Hemophilia: treatment options in the twenty‐first century

  2003cited by this paper
• Progress in haemophilic care: ethical issues

  2002cited by this paper
• Structural and functional characterization of B-domain deleted recombinant factor VIII.

  2001cited by this paper
• Carbohydrate analysis by high-performance anion-exchange chromatography with pulsed amperometric detection: The potential is still growing

  2000influential reference
• Insect cells as hosts for the expression of recombinant glycoproteins

  1999cited by this paper
• Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.

  1999cited by this paper
• Appropriate mammalian expression systems for biopharmaceuticals.

  1998cited by this paper
• Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’

  1996cited by this paper
• Elucidation of N‐linked oligosaccharide structures of recombinant human factor VIII using fluorophore‐assisted carbohydrate electrophoresis

  1996cited by this paper
• Amino acid residues 721-729 are required for full factor VIII activity.

  1995cited by this paper
• Characterization of a recombinant antihaemophilia-A factor (factor VIII-delta II) by matrix-assisted laser desorption/ionization mass spectrometry.

  1995cited by this paper
• Structural Analysis of the Oligosaccharides Derived from Glycodelin, a Human Glycoprotein with Potent Immunosuppressive and Contraceptive Activities (*)

  1995cited by this paper
• Modern treatment of haemophilia.

  1995cited by this paper
• Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide.

  1994cited by this paper
• Novel Asn-linked oligosaccharides terminating in GaINAcβ(1→4)[Fuca(1→3)]GlcNAcB(1→•) are present in recombinant human Protein C expressed in human kidney 293 cells

  1993cited by this paper
• Novel Asn-linked oligosaccharides terminating in GalNAc beta (1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.) are present in recombinant human protein C expressed in human kidney 293 cells.

  1993cited by this paper
• Human urokinase contains GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) as a novel terminal element in N-linked carbohydrate chains.

  1992cited by this paper
• Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells.

  1992influential reference
• Human urokinase contains Ga1NAcβ(1‐4)[Fucα(1‐3)]G1cNAcβ(1‐2) as a novel terminal element in N‐linked carbohydrate chains

  1992cited by this paper
• Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.

  1991influential reference
• Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.

  1991cited by this paper
• Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology

  1991cited by this paper
• Association of the factor VIII light chain with von Willebrand factor.

  1988cited by this paper
• Comparative study of the oligosaccharides released from baby hamster kidney cells and their polyoma transformant by hydrazinolysis.

  1984cited by this paper
• Treatment

  1973cited by this paper

• Generation and characterization of a HEK293 cell line optimized for recombinant adeno-associated virus production

  2026cites this paper
• Navigating the complexity of biologics and biosimilar: structural, clinical, and regulatory insights

  2026cites this paper
• A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A.

  2025cites this paper
• Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins

  2025cites this paper
• rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation

  2025cites this paper
• Factor VIII a coagulation co-factor is a relevant survival factor in bladder cancer cell lines.

  2025cites this paper
• Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

  2024influential citation
• Genotype-dependent N-glycosylation and newly exposed O-glycosylation affect plasmin-induced cleavage of histidine-rich glycoprotein (HRG)

  2024cites this paper
• Simoctocog alfa (Nuwiq®) in children: early steps in life’s journey for people with severe hemophilia A

  2024cites this paper
• Investigation into the efficiency of diverse N‐linking oligosaccharyltransferases for glycoengineering using a standardised cell‐free assay

  2024influential citation
• Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study

  2023cites this paper
• Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects

  2023cites this paper
• No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients

  2023cites this paper
• Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice—Brief Report

  2023cites this paper
• Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients

  2023cites this paper
• Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method

  2023cites this paper
• Site-specific glycosylation of proteoglycans: a revisited frontier in proteoglycan research.

  2022cites this paper
• Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII

  2022cites this paper
• Immune Responses to Plasma-Derived Versus Recombinant FVIII Products

  2021cites this paper
• Glyco-engineered HEK 293-F cell lines for the production of therapeutic glycoproteins with human N-glycosylation and improved pharmacokinetics.

  2021cites this paper
• Haemophilia

  2021cites this paper
• HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors

  2021cites this paper
• Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies

  2021cites this paper
• Commentary on “Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach” ‐ Will we ever be able to avoid inhibitor formation in hemophilia A?

  2021cites this paper
• Affecting HEK293 Cell Growth and Production Performance by Modifying the Expression of Specific Genes

  2021cites this paper
• Observational study of efficacy and safety of human cell line–derived recombinant factor VIII in Canadian adults with moderately severe and severe haemophilia A

  2021cites this paper
• Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study

  2021cites this paper
• Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products

  2021cites this paper
• University of Birmingham Removal of mannose-ending glycan at Asn2118 abrogates FVIII presentation by human monocyte-derived dendritic cells

  2020cites this paper
• Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy.

  2020cites this paper
• Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

  2020cites this paper
• Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII

  2020cites this paper
• The availability of new drugs for hemophilia treatment

  2020cites this paper
• Comprehensive N‐ and O‐glycosylation mapping of human coagulation factor V

  2020cites this paper
• An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A

  2020cites this paper
• Tolerating Factor VIII: Recent Progress

  2020cites this paper
• Therapeutic Glycoprotein in Mammalian

  2020cites this paper
• Estimation of Nuwiq® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study

  2019cites this paper
• Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

  2019cites this paper
• An update on the ‘danger theory’ in inhibitor development in hemophilia A

  2019cites this paper
• A human expression system based on HEK293 for the stable production of recombinant erythropoietin

  2019cites this paper
• How Full-Length FVIII Benefits from Its Heterogeneity – Insights into the Role of the B-Domain

  2019cites this paper
• Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation

  2019cites this paper
• Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A

  2018cites this paper
• Review of immune tolerance induction in hemophilia A.

  2018cites this paper
• Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.

  2018influential citation
• Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

  2018cites this paper
• Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate®: Final report from a prospective study

  2018cites this paper
• Platforms for Recombinant Therapeutic Glycoprotein Production.

  2018cites this paper
• Glycosylation

  2018cites this paper
• Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A

  2018cites this paper
• Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective

  2018cites this paper
• Recombinant factor VIII: past, present and future of treatment of hemophilia A.

  2018cites this paper
• In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications

  2018cites this paper
• N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice

  2018cites this paper
• Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

  2018cites this paper
• Glycosylation control technologies for recombinant therapeutic proteins

  2018cites this paper
• Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

  2018cites this paper
• Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

  2018cites this paper
• Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

  2018cites this paper
• Simoctocog alfa for the treatment of hemophilia A

  2017influential citation
• Protéines de fusion vwf glycosylées à pharmacocinétique améliorée

  2017cites this paper
• Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.

  2017cites this paper
• PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

  2017cites this paper
• Expression and characterization of a codon‐optimized blood coagulation factor VIII

  2017cites this paper
• Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa)

  2017cites this paper
• Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1

  2017cites this paper
• Therapeutic glycoprotein production in mammalian cells.

  2017influential citation
• Current and emerging factor VIII replacement products for hemophilia A

  2017cites this paper
• Stratégies thérapeutiques contre la réponse immunitaire anti-Facteur VIII chez l'hémophile A : par modification de la structure du FVIII, par inhibition de la signalisation des lymphocytes B

  2017cites this paper
• To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.

  2017cites this paper
• Production of recombinant coagulation factors: Are humans the best host cells?

  2017cites this paper
• Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII

  2017cites this paper
• Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

  2017cites this paper
• Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

  2016cites this paper
• Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A

  2016cites this paper
• Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

  2016cites this paper
• Novel, human cell line‐derived recombinant factor VIII (Human‐cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

  2016cites this paper
• Emerging drugs for the treatment of hemophilia A and B

  2016cites this paper
• Key insights to understand the immunogenicity of FVIII products

  2016cites this paper
• The factor VIII protein and its function.

  2016cites this paper
• The safety of pharmacologic options for the treatment of persons with hemophilia

  2016cites this paper
• New products for the treatment of haemophilia

  2016cites this paper
• Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

  2016cites this paper
• Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor

  2016cites this paper
• Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience

  2016influential citation
• Detection and Prediction of Factor VIII Antibody Formation in Congenital and Acquired Haemophilia A

  2016cites this paper
• Industrial production of clotting factors: Challenges of expression, and choice of host cells

  2015cites this paper
• Turoctocog alfa (recombinant factor VIII)

  2015cites this paper
• Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.

  2015cites this paper
• Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

  2015cites this paper
• Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity

  2015cites this paper
• Using glyco-engineering to produce therapeutic proteins

  2015influential citation
• Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

  2015influential citation
• A new recombinant factor VIII: from genetics to clinical use

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Spotlight on the human factor: building a foundation for the future of haemophilia A management

  2015cites this paper
• The application of targeted mass spectrometry-based strategies to the detection and localization of post-translational modifications.

  2015cites this paper
• Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells

  2015cites this paper
• Mass spectrometry for glycosylation analysis of biopharmaceuticals

  2015cites this paper